Literature DB >> 19168853

Gigaxonin controls vimentin organization through a tubulin chaperone-independent pathway.

Don W Cleveland1, Koji Yamanaka, Pascale Bomont.   

Abstract

Gigaxonin mutations cause the fatal human neurodegenerative disorder giant axonal neuropathy (GAN). Broad deterioration of the nervous system in GAN patients is accompanied by massive disorganization of intermediate filaments (IFs) both in neurons and many non-neuronal cells. With newly developed antibodies, gigaxonin is now shown to be expressed at extremely low levels throughout the nervous system. In lymphoblast cell lines derived from severe and mild forms of GAN, mutations in gigaxonin are shown to yield highly unstable proteins, thereby permitting a rapid diagnostic test for the spectrum of GAN mutations as an alternative to invasive nerve biopsy or systematic sequencing of the GAN gene. Gigaxonin has been proposed as a substrate adaptor for an E3 ubiquitin ligase, which affects proteasome-dependent degradation of microtubule-related proteins including MAP1B, MAP8 and the tubulin folding chaperone TBCB. We demonstrate that, unlike its counterpart TBCE, TBCB only moderately destabilizes microtubules. Neither TBCB abundance nor microtubule organization or densities are altered in GAN mutant fibroblasts, thus demonstrating that altered TBCB levels are not primary determinants of IF disorganization in GAN. Characteristic GAN mutant-induced ovoid aggregates of vimentin are not produced in normal fibroblasts after disrupting microtubule assembly, either by TBCE overexpression or depolymerizing drugs. Thus, IF disorganization in GAN fibroblasts is independent of TBCB and microtubule loss and must be regulated by a yet unidentified mechanism.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19168853      PMCID: PMC2664145          DOI: 10.1093/hmg/ddp044

Source DB:  PubMed          Journal:  Hum Mol Genet        ISSN: 0964-6906            Impact factor:   6.150


  52 in total

1.  Identification of seven novel mutations in the GAN gene.

Authors:  P Bomont; C Ioos; C Yalcinkaya; R Korinthenberg; J M Vallat; S Assami; A Munnich; B Chabrol; G Kurlemann; M Tazir; M Koenig
Journal:  Hum Mutat       Date:  2003-04       Impact factor: 4.878

2.  Intermediate filament aggregation in fibroblasts of giant axonal neuropathy patients is aggravated in non dividing cells and by microtubule destabilization.

Authors:  Pascale Bomont; Michel Koenig
Journal:  Hum Mol Genet       Date:  2003-04-15       Impact factor: 6.150

3.  Tubulin folding cofactor D is a microtubule destabilizing protein.

Authors:  L Martín; M L Fanarraga; K Aloria; J C Zabala
Journal:  FEBS Lett       Date:  2000-03-17       Impact factor: 4.124

4.  The gene encoding gigaxonin, a new member of the cytoskeletal BTB/kelch repeat family, is mutated in giant axonal neuropathy.

Authors:  P Bomont; L Cavalier; F Blondeau; C Ben Hamida; S Belal; M Tazir; E Demir; H Topaloglu; R Korinthenberg; B Tüysüz; P Landrieu; F Hentati; M Koenig
Journal:  Nat Genet       Date:  2000-11       Impact factor: 38.330

5.  Giant axonal neuropathy (GAN): case report and two novel mutations in the gigaxonin gene.

Authors:  G Kuhlenbäumer; P Young; C Oberwittler; G Hünermund; A Schirmacher; K Domschke; B Ringelstein; F Stögbauer
Journal:  Neurology       Date:  2002-04-23       Impact factor: 9.910

6.  BTB proteins are substrate-specific adaptors in an SCF-like modular ubiquitin ligase containing CUL-3.

Authors:  Lai Xu; Yue Wei; Jerome Reboul; Philippe Vaglio; Tae-Ho Shin; Marc Vidal; Stephen J Elledge; J Wade Harper
Journal:  Nature       Date:  2003-09-03       Impact factor: 49.962

7.  The BTB protein MEL-26 is a substrate-specific adaptor of the CUL-3 ubiquitin-ligase.

Authors:  Lionel Pintard; John H Willis; Andrew Willems; Jacque-Lynne F Johnson; Martin Srayko; Thimo Kurz; Sarah Glaser; Paul E Mains; Mike Tyers; Bruce Bowerman; Matthias Peter
Journal:  Nature       Date:  2003-09-03       Impact factor: 49.962

8.  Genotype-phenotype analysis in patients with giant axonal neuropathy (GAN).

Authors:  Olga Koop; Anja Schirmacher; Eva Nelis; Vincent Timmerman; Peter De Jonghe; Bernd Ringelstein; Vedrana Milic Rasic; Philippe Evrard; Jutta Gärtner; Kristl G Claeys; Silke Appenzeller; Bernd Rautenstrauss; Kathrin Hühne; Maria A Ramos-Arroyo; Helmut Wörle; Jukka S Moilanen; Simon Hammans; Gregor Kuhlenbäumer
Journal:  Neuromuscul Disord       Date:  2007-06-22       Impact factor: 4.296

9.  ADP ribosylation factor-like protein 2 (Arl2) regulates the interaction of tubulin-folding cofactor D with native tubulin.

Authors:  A Bhamidipati; S A Lewis; N J Cowan
Journal:  J Cell Biol       Date:  2000-05-29       Impact factor: 10.539

10.  Microtubule-associated protein 1B: a neuronal binding partner for gigaxonin.

Authors:  Jianqing Ding; Jia-Jia Liu; Anthony S Kowal; Timothy Nardine; Priyanka Bhattacharya; Arthur Lee; Yanmin Yang
Journal:  J Cell Biol       Date:  2002-07-29       Impact factor: 10.539

View more
  20 in total

1.  Intermediate filament protein accumulation in motor neurons derived from giant axonal neuropathy iPSCs rescued by restoration of gigaxonin.

Authors:  Bethany L Johnson-Kerner; Faizzan S Ahmad; Alejandro Garcia Diaz; John Palmer Greene; Steven J Gray; Richard Jude Samulski; Wendy K Chung; Rudy Van Coster; Paul Maertens; Scott A Noggle; Christopher E Henderson; Hynek Wichterle
Journal:  Hum Mol Genet       Date:  2014-11-04       Impact factor: 6.150

2.  p16 Protein and gigaxonin are associated with the ubiquitination of NFκB in cisplatin-induced senescence of cancer cells.

Authors:  Mysore S Veena; Reason Wilken; Jun-Ying Zheng; Ankur Gholkar; Natarajan Venkatesan; Darshni Vira; Sameer Ahmed; Saroj K Basak; Clifton L Dalgard; Sandhiya Ravichandran; Raj K Batra; Noriyuki Kasahara; David Elashoff; Michael C Fishbein; Julian P Whitelegge; Jorge Z Torres; Marilene B Wang; Eri S Srivatsan
Journal:  J Biol Chem       Date:  2014-10-20       Impact factor: 5.157

3.  Giant axonal neuropathy-associated gigaxonin mutations impair intermediate filament protein degradation.

Authors:  Saleemulla Mahammad; S N Prasanna Murthy; Alessandro Didonna; Boris Grin; Eitan Israeli; Rodolphe Perrot; Pascale Bomont; Jean-Pierre Julien; Edward Kuczmarski; Puneet Opal; Robert D Goldman
Journal:  J Clin Invest       Date:  2013-04-15       Impact factor: 14.808

Review 4.  The ubiquitin proteasome system in neuropathology.

Authors:  Norman L Lehman
Journal:  Acta Neuropathol       Date:  2009-07-14       Impact factor: 17.088

Review 5.  A review of gigaxonin mutations in giant axonal neuropathy (GAN) and cancer.

Authors:  James J Kang; Isabelle Y Liu; Marilene B Wang; Eri S Srivatsan
Journal:  Hum Genet       Date:  2016-03-29       Impact factor: 4.132

Review 6.  Cullin 3-Based Ubiquitin Ligases as Master Regulators of Mammalian Cell Differentiation.

Authors:  Wolfgang Dubiel; Dawadschargal Dubiel; Dieter A Wolf; Michael Naumann
Journal:  Trends Biochem Sci       Date:  2017-12-14       Impact factor: 13.807

7.  Sonic Hedgehog repression underlies gigaxonin mutation-induced motor deficits in giant axonal neuropathy.

Authors:  Yoan Arribat; Karolina S Mysiak; Léa Lescouzères; Alexia Boizot; Maxime Ruiz; Mireille Rossel; Pascale Bomont
Journal:  J Clin Invest       Date:  2019-12-02       Impact factor: 14.808

8.  Intermediate filament aggregates cause mitochondrial dysmotility and increase energy demands in giant axonal neuropathy.

Authors:  Eitan Israeli; Dilyan I Dryanovski; Paul T Schumacker; Navdeep S Chandel; Jeffrey D Singer; Jean P Julien; Robert D Goldman; Puneet Opal
Journal:  Hum Mol Genet       Date:  2016-03-21       Impact factor: 6.150

9.  Decreased KLHL3 expression is involved in the pathogenesis of pseudohypoaldosteronism type II caused by cullin 3 mutation in vivo.

Authors:  Sayaka Yoshida; Yuya Araki; Takayasu Mori; Emi Sasaki; Yuri Kasagi; Kiyoshi Isobe; Koichiro Susa; Yuichi Inoue; Pascale Bomont; Tomokazu Okado; Tatemitsu Rai; Shinichi Uchida; Eisei Sohara
Journal:  Clin Exp Nephrol       Date:  2018-06-05       Impact factor: 2.801

10.  Gigaxonin glycosylation regulates intermediate filament turnover and may impact giant axonal neuropathy etiology or treatment

Authors:  Po-Han Chen; Jimin Hu; Jianli Wu; Duc T Huynh; Timothy J Smith; Samuel Pan; Brittany J Bisnett; Alexander B Smith; Annie Lu; Brett M Condon; Jen-Tsan Chi; Michael Boyce
Journal:  JCI Insight       Date:  2019-11-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.